Good day, and thank you for standing by. Welcome to the Q4 2025 Amatec, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker, Kevin Coleman, VP of Investor Relations and Treasurer. Please go ahead.

Thank you, Crystal. Good morning and welcome to Amitek's fourth quarter 2025 earnings conference call. Joining me today are Dave Zipiko, Chairman and Chief Executive Officer, and Dala Puri, Executive Vice President and Chief Financial Officer. During the course of today's call, we will be making forward-looking statements which are subject to change based on various risk factors and uncertainties that may cause actual results to differ significantly from expectations. A detailed discussion of the risk and uncertainties that may affect our future results is contained in Amitec's filings with the SEC. Amitec disclaims any intention or obligation to update or revise any forward-looking statements. Any references made on this call to historical results will be on an adjusted basis, excluding after-tax acquisition-related intangible amortization and excluding acquisition-related cost. Reconciliations between GAAP and adjusted measures can be found in our press release and on the Investors section of our website. We'll begin today's call with prepared remarks and then we'll open it up for questions. I'll now turn the meeting over to Dave.

Thank you, Kevin, and good morning, everyone. Amatek completed a strong year with excellent results in the fourth quarter, highlighted by double-digit growth in sales, orders, and operating profit, robust core margin expansion, strong cash flow growth, and earnings per share ahead of our expectations. In the quarter, we established records for sales, orders, operating income, EBITDA, diluted earnings per share, operating cash flow, and free cash flow. And today we announced the acquisition of LKC Technologies, an attractive technology acquisition, which broadens our medtech exposure. I'll provide more details on LKC shortly. Now let me turn to our fourth quarter results. Fourth quarter sales were a record $2 billion, up 13% from the same period in 2024. Organic sales were up 5%. percent. Acquisitions added seven points in the quarter, and foreign currency was a one-point tailwind. Very strong in the quarter with overall orders up 18 percent to a record $2 billion and organic orders up 7 percent versus the prior year, leading to a record backlog of $3.58 billion. Growth consistently improved throughout the year, with the fourth quarter growth the strongest of the year. Operating income was a record $523 million, a 12 percent increase over the fourth quarter of 2024. Operating margins were 26.2% in the quarter. Quarter margins were an impressive 27.6% up 100 basis points. EBITDA in the quarter was a record $618 million up 10% versus the prior year and EBITDA margins a strong 30.9%. Performance led to strong cash generation with free cash flow a record $527 million in the quarter, up 6% versus last year's fourth quarter, and free cash flow to net income conversion of 132%. Diluted earnings per share were a record $2.01, up 7% versus the fourth quarter of 2024, and above our guidance range of $1.90 to $1.95 per share. Adjusting for an abnormally low tax rate in last year's fourth quarter, diluted earnings per share would have increased 11% in the quarter on a 5% increase in organic sales, reflecting strong incremental margins. Let me provide some additional details at the operating group level, electronic instruments group. EIG delivered excellent operating performance in the fourth quarter, with record sales and operating profit, along with impressive core margin expansion. EIG sales were $1.37 billion dollars up 13 percent from last year's fourth quarter organic sales were up two percent acquisitions added 10 points foreign currency was a one point tailwind encouraged by the organic sales growth in the quarter and the steady improvement in eig growth rates throughout 2025. eig's fourth quarter operating income was a record 413.7 million dollars up seven percent versus the prior year for operating margins were a robust 32.3 percent up 50 basis points from the prior year, completed an outstanding year with very strong broad-based growth and excellent operating performance in the quarter. EMG's fourth quarter sales were $629 million, up 15% versus the prior year. Organic sales were up an impressive 14%, and foreign currency was a one-point tailwind. Sales growth was strong across all EMG divisions, with each growing double digits organically in the quarter. EMG's operating income in the fourth quarter was $142.5 million dollars, up a sizable 28 percent compared to the prior year period, while EMG's fourth quarter operating margins were 22.7 percent, up 240 basis points versus the fourth quarter of 2024. Now for the full year results. Amitek delivered excellent overall results in 2025, establishing annual records for sales, operating income, operating margin, EBITDA, and diluted earnings per share. Overall sales for the year were $7.4 billion, up 7% from 2024. Operating income for 2025 was $1.94 billion, up 7%, and operating margins were 26.2%, up 10 basis points from the prior year period, while core margins were up a very strong 80 basis points. EBITDA for the year was $2.33 billion, up 7%, with EBITDA margins a very strong, 31.5%. Full-year 2025 earnings were $7.43 per delivery this year, up 9% versus a prior year. We also delivered strong cash flows in 2025, providing us with significant capital to deploy on strategic acquisitions, with free cash flow and net income conversion of 113%. I'm very proud of our performance in 2025. Our businesses successfully navigated through sluggish industrial markets and ongoing macroeconomic uncertainty and delivered excellent results. Thank you to all Amatec colleagues for your outstanding contributions and hard work in delivering on our commitments to our customers and shareholders. Amatec is well positioned for continued long-term success given your efforts. Turning to Acquisitions and Capital Deployment. In 2025, we completed the acquisitions of Ferro Technologies and Kern Micro-Technique for approximately $1 billion, acquiring approximately $400 million in annual sales. The integration of both businesses is going well as they integrate the Amatec growth model into their businesses. Now switching to our most recent acquisition, LKC Technologies. LKC is a leading provider of innovative technologies that enable effective diagnosis and management of ophthalmic conditions. Their advanced technology solutions help doctors test and monitor eye health and are designed to detect early signs of diabetic retinopathy and other serious eye conditions that can lead to vision loss. A combination of LKC with our ultra-precision technologies Rikert business provides attractive market expansion opportunities and creates a broader ophthalmic performance. LKC was privately held and headquartered in Germantown, Maryland. I'm excited to welcome all LKC Technologies colleagues to the Ametek family. With our robust balance sheet, strong cash flows, and disciplined approach to capital deployment, Ametek is well positioned to continue driving long-term value through our acquisition strategy. We are encouraged by our strong pipeline of high-quality acquisition candidates, and our significant financial capacity provides us with the flexibility to deploy over $5 billion in capital while maintaining an investment-grade credit rating. Our priority for capital deployment remains acquisitions, while our strong cash flow provides us with the flexibility to opportunistically repurchase shares and pay a consistently increasing dividend. We also continue to focus on ensuring Amatec is strategically positioned for long-term sustainable growth through continued investments back into our business. These investments have strengthened our leadership position within our niche markets, helped open up new growth markets and attractive adjacencies, and accelerated our new product development and technology innovation. In 2025, we invested an incremental $90 million in support of these growth initiatives, with the majority of these going into our research, development, engineering, sales and marketing, and digital initiatives. And in 2026, we expect to invest an incremental $100 million. We're seeing great results from these investments. In the fourth quarter, our Vitality Index, which measures sales of new products introduced over the last three years, was an outstanding 30%. This is a couple of examples of how our businesses are leveraging their technology innovation efforts and product portfolios to help strategically expand their presence within attractive market The first business is Amitec Spectro. Spectro is a leading provider of advanced analytical instrumentation for use in critical industrial, environmental, research, and academia applications. Spectro's products and solutions provide highly accurate, reliable, and efficient elemental analysis. Spectro has recently introduced a new product family of elemental analysis instruments, broadening their technology, product capabilities, and market reach. These new products, the SpectroMax and the XSort, have seen outstanding demand as rapidly rising commodity prices have increased the importance of precise and accurate metals analysis within a wide range of applications. We are also seeing growing demand in particular within our European defense businesses as our differentiated technology capabilities are well positioned to benefit from the expanding defense spending in the region. Our defense businesses provide a wide range of ruggedized high performance solutions for a diverse set of mission critical defense applications and we continue to win content on new programs given our strong design and engineering capabilities. To share a few examples, Amatec's Rotron and air technology businesses are providing advanced cooling solutions for use on a number of European air defense systems, providing integrated high-performance computing systems for European aircraft and communications platforms, and our power and data systems businesses is supplying power generation systems for a number of UAV platforms for our businesses and developing the critical products and technologies needed by our customers. Now shifting to our outlook for the year ahead, for 2026, we expect overall sales to be up mid to high single digits on a percentage basis, with organic sales expected to increase low to mid single digits versus the prior year. Included earnings per share for the year are expected to be in the range of $7.87 to $8.07, up 6% to 9% compared to last year's results. First quarter, we anticipate overall sales to be up approximately 10% versus the prior year's first quarter, with adjusted earnings of $1.90 to $1.95 per share, up 6% to 9% versus the prior year. To summarize, Ametek delivered a strong finish to the year with excellent performance in the fourth quarter, reflecting the strength of our portfolio and our ability to execute our growth strategy. We entered 2026 with a record backlog and solid momentum given the strong sales and orders growth we saw in the second half of 2025. Our differentiated technologies and deep industry expertise continue to position us well in attractive niche markets additionally we have significant capital to deploy on strategic acquisitions and a track record of delivering strong returns on capital lastly our proven operating capabilities allow us to deliver strong incremental margins and manage through economic or geopolitical uncertainties with a focus on innovation operational excellence and disciplined capital allocation. We're confident in our ability to drive continued growth and create long-term value for our shareholders in 2026 and beyond. I will now turn it over to Dalla Puri. We'll cover some of the financial details of the quarter, then we'll be glad to take your questions. Dalla?

Thank you, Dave, and good morning, everyone. As Dave noted, I'm establishing records for orders, sales, operating income, earnings per share, and... Now let me provide some additional financial highlights for the fourth quarter, the full year, as well as some additional guidance for 2026. Fourth quarter, general and administrative expenses were $33 million, up $4 million from the prior year due to higher charitable donations in the period. For the full year, general and administrative expenses were up $10 million. As a percentage of sales, full-year G&A expense was 1.6%, up slightly. For 2026, general and administrative expenses are expected to be approximately 1.5%. Fourth quarter, other expenses were up $6 million compared to the fourth quarter. For 2026, we expect other operating expenses to be largely in line with 2025 levels. The effective tax rate in the quarter was 16.3%, up from 12.8% in the fourth quarter of 2024. For the full year, the effective tax rate was 17.8%. For 2026, we anticipate our effective tax rate to be between 18.5% and 19.5%. As we have stated in the past, actual quarterly tax rates can differ dramatically, either positively or negatively, from this full year estimated $7 million in the fourth quarter and $130 million for the full year. Capital expenditures in 2026 are expected to be approximately $160 million, or about 2% of sales. Depreciation and amortization expense in the quarter was $106 million, and for the full year was $423 million. In 2026, we expect depreciation and amortization to be approximately $430 million, including after-tax acquisition-related intangible amortization of approximately $210 million, or $0.91 per day. For the quarter, operating working capital was 16.5% of sales, a 30 basis point improvement versus the fourth quarter of 2024. Operating cash flow in the quarter was a record $584 million. Free cash flow was also a record in the quarter, up 6% to $527 million, with outstanding free cash flow conversion of 132% for the quarter. Free cash flow for 2025 was $1.7 billion, with full year free cash flow conversion also very strong at 113% of net income. For 2026, we expect free cash flow conversion to be between 110 and 115% of net income. Total debt at year end was $2.3 billion, up $200 million from the end of 2024 due to the acquisition of Faro Technologies. Offsetting this debt is cash-in-cash equivalence of $458 million. During the quarter, we spent approximately $285 million on share repurchases, bringing our total share repurchases for the year to approximately $440 million. We continue to have significant financial capacity and strategies. We demonstrated our financial flexibility in 2025 by deploying over $1.8 billion on acquisitions, share repurchases, and dividends, all while maintaining our financial capacity and a conservative balance sheet. At the end of 2025, our gross debt to EBITDA ratio was one times, and our net debt to EBITDA ratio was 0.8 times, essentially unchanged from the end of 2020. In summary, we delivered strong fourth quarter and full year operating results, highlighted by record revenue, record earnings, robust margin growth, and excellent cash flow generation. With a proven strategy, significant capital deployment capacity, and a strong track record of execution, we are well positioned to continue delivering exceptional results.

Thanks, Alec. Crystal, could we please open the lines for questions?

Thank you. As a reminder, to ask a question, you will need to press star 1 on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by. We compile our Q&A roster. And our first question will come from Matt Somerville from DA Davidson. Your line is open. David, I was hoping you could drill deeper

into the medical portfolio and their performance therein across both EIG and EMG and how we should be thinking about kind of the medium to long-term algorithm associated with Paragon and Rowland and some of the bigger buckets in medical and then I

have a follow-up thank you sure it's about 21% of our business now the broader healthcare exposure if you look at the health across both groups Paragon and rolling, driving the results, double digits in Q4. That was a very good quarter, up low double digits. And for the full year, 25, they were up high single digits. And we're thinking for 26, it will be up mid-single digits. Our initial guide is mid-single digits, more challenging comps, but still very healthy businesses and performing well.

I was wondering if you could talk about how you're thinking about strategic price capture kind of going forward, you know, after passing through this multi-year period where you had, you know, putting meaningful inflation, and then obviously, you know, you had the tariff pressure. So what's kind of the go-forward, you know, price algorithm? What does that look like for Amitech now?

For the fourth quarter of 25, we had a positive, our pricing offset both inflation and tariffs. So, you know, we think that that is going to be what's going to happen in 26. So for the full year 26, we're confident we can offset inflation and the existing known tariffs. So we're getting, you know, we have highly differentiated businesses, Amitek product portfolio, leadership in niche markets around the globe. These are mission-critical products. The pricing is not going backwards. It's going to stick. The vast majority of it is price increases, not just kind of offsets. So we had a good pricing situation. As I mentioned in my prepared remarks, we have a refreshed product portfolio, 30% vitality, mission-critical products. So we really have done this for quite a while and don't see any change. So I think we'll be positive when you take into account inflation and tariffs for the year. Thank you, David. Thank you, Matt.

Thank you. Our next question comes from Dean Jure from RBC Capital Markets. Your line is open.

Thank you. Good morning, everyone.

Good morning, Dean.

Hey, maybe we can step back and, Dave, do your typical run through the end markets, key platforms. It sounded like everything in medical was certainly hitting expectations. and if you could touch on any kind of regional dynamics as well.

Process businesses, we're up mid-teens in the fourth quarter from recent acquisitions. So we acquired the Farrell business, the Kern business, and we bring those in. They're at lower margins, and we're improving them as we go. But that group grew low single digits organically in that quarter. So that's the first time we saw a low single-digit organic growth in process. We're pretty happy with that. We saw continued improvements throughout the whole year, as I said, the most positive in the fourth quarter. We're encouraged by that finish to the year, and we talked about before we see a very strong pipeline of growing opportunities in our broader process and analytical instrumentation markets. For the full year 2026, we expect organic sales for our process segment to be up low single digits. Let's talk about our aerospace and defense businesses. They completed an outstanding year with low double-digit growth in both overall and organic sales in the quarter. Similar to the four-year growth was broad-based, strongest orders, strongest growth across our commercial OE and aftermarket businesses in the quarter. Our businesses are well-positioned with strong and expanding content on a wide variety of aerospace and defense platforms and looking ahead we expect another strong year high single digit organic growth in 2026 and really balanced across both our commercial and defense businesses jumping next to our power business in organic sales we're up mid single digits portal is strongest within within our rtds and power instruments businesses by global grid modernization and applications supporting the data center build out talked a little bit in the last meeting we have applications in power generation backup power micro grids power system simulation services all supporting their broader data center ecosystem and delivering power to the ecosystem looking ahead to 2026 we expect organic sales for our power businesses to be up mid-single digits. And finally, our automation and engineer solutions businesses delivered another outstanding quarter with low double-digit overall and organic sales growth. Growth was again broad-based across our automation and engineer solutions businesses with our Paragon medical businesses delivering the strongest growth. For 2026, we expect sales for our automation and engineer solutions businesses to be up mid single digits organically. And I think you asked about the geography also, James. Yeah. Yeah, we had, you know, both U.S. and international sales were up mid single digits. So, so it was, you know, kind of good strength across the board. In the U.S., we were up MSD, mid single digits, driven by strength in our automation and then engineer solutions business. In Europe, we were up low single digits, driven by strength and aerospace and our automation businesses. And Asia was up 10%. We were very pleased. China was up low double digits for us, driven by our process, power, and automation businesses. And again, Asia was up 10%. If we take China out of Asia, Asia was up high single digits. So Asia was pretty much strong across the board. So pretty good performance geographically across the board. All good to

here. Just a quick follow-up. You talk about record backlog. What kind of conversion should we expect in 2026 of backlog? I mean, I know typical you're at like a 30% conversion, but with the recent kind of expansion, it's been closer to 50. How does that shape up for 26?

It's in the same ballpark. With our long cycle businesses, our aerospace and defense business with some of those are multi-year but uh there's plenty for us to ship near term so we're pretty pretty uh optimistic about the order pipelines we we had good orders throughout the quarter december was the strongest quarter december was the strongest record quarter for us in one month and we also started the year strong so so you know orders are good again the backlog is With our multiple industries, it's a little bit difficult, but you're right. It's between that 30% and 50% number, but we're in good shape, and it's feeling good with the strength.

Great to hear.

Thank you, Dean.

Thank you. Our next question comes from Andrew Bliscaglia from BNP Parapas. Your line is open.

Hey, good morning, everyone. Good morning, Andrew. I was hoping to focus on EIG just that you know it sounds like you know that organic growth of two percent a little bit below kind of what you had expected because you expected the full year to grow year over year so I imagine in process and analytical instrumentation that maybe didn't come to growth didn't come to fruition the way you thought it would what are your expectations into 2026 for that segment, or sub-segment, and project activity converting?

Yeah, just if you go back to the beginning of 2025, we actually had negative organic growth in the first couple of quarters in our process businesses, and those improved. So we actually were positive in Q4. So we were pretty pleased with the performance of EIG turning positive in Q4 on the back of the process of business performance. If I look at 2026, you know, we have our overall sales, I already mentioned in the prepared remarks, is up mid to high single digits, with organic up low to mid single digits. And we think both of our businesses will have low to mid single digit organic growth. So both EIG and EMG overall will be up mid to high single digits, and both will have organic growth of low to mid single digits.

Okay, got it. And, you know, that outlook in EMG, your sales were so strong in Q4. Was there something out of the ordinary unusual that would drive that 15% growth that just won't repeat going forward?

No, I think that, as I mentioned in the prepared remarks, every division within EMG had double-digit growth. There's really a lot of strength there. I mean, if you're going to get some tougher comps next year, but we're performing well. We have strong execution, disciplined operations. We're gaining momentum in the portfolio. EMG recovered nicely. automation and medtech are solid A&D remains strong with good backlogs so I think what you might be seeing there is the guide's a little bit prudent this early in the year but we feel good about EMG in 2026

Alright, fair enough, thank you

Thank you, our next question comes from Brett Lindsey from Mizzouho, your line is open

Hey, good morning all

Good morning Brett

Hey, I wanted to just come back to the kind of the pricing dynamic. I know there's a lot of fits and starts on tariffs last year and subsequent pricing. Any signs of pre-buy or pre-build in some of those channels as maybe some of that de-stock has turned to restock and customers are maybe looking to get ahead of some of the price last year?

I think it seems like we've, you know, there's a lot of things we're dealing with and uncertainties and related to the broader de-gulbalization. But I think all that stuff happens. I think we're, you know, we're more of a more normalized, it feels like it's more normalized now where you don't have buy heads, you don't have things like that. And so it feels more normal than it did in 25 at the beginning of 26.

Okay, great. Great. And then just to follow up on price and cost, maybe discuss your actual pricing expectation for 2026. And then how are you thinking about price cost spread for the year? I know we're getting a little bit of metals inflation here.

We're not giving a specific target, but what we will say is in the fourth quarter, as I mentioned to Matt, we offset price price offset inflation plus tariffs plus in about 50 basis points so it was very strong and I expect a similar kind of performance next year that's our target so so there's our different businesses or different levels of inflation there's dynamics but we have a strong history of because of the product portfolio and special place in the value chain we have with our customers being able to offset price, offset inflation and tariffs with price. So that's

going to continue. All right. Great. Thanks, Dave. Thank you. Our next question comes from Andrew Obin from Bank of America. Your line is open. Oh, yes. Good morning. Can we just get an

update on FARO acquisition? What are you seeing? What's the progress has been? What are the key

learnings designed and develops advanced 3d metrology and digital reality solutions these include product families like measurement arms laser scanners laser trackers integrated process it's an excellent strategic fit with our creaform business so we have a business that's complementary to it and complements our metrology capabilities so it's uh and we acquired the business and we think we can add meaningful value to Ferro. So along with the elimination of the public company cost and the integration of the Amitek's global infrastructure, we think there's a tremendous amount of synergy. So we acquired the business for about 2.7 times and we feel that the cost synergies will allow us to more than double EBDA margins from the current you know, mid-teens level to a 30% level and achieve a 10% return on invested capital by year three. And that was the plan going in, and it's still, we're more confident than ever we're going to be able to do that. We have made moves on integrating the business. We formed two business units. One's more the metrology business unit, and one's more the digital reality business. So those are people coming from Legacy Emotech and Faro in both businesses, and that's going extremely well. You'll see in the lease we put out, we have some one-time charges with that. It was about $17.6 million, I believe. So that's allowing us to get the kinds of improvements that we're getting in the business, And that's why there's, you know, quite a big gap between our core margins that I mentioned and the reported margins. You've got the – along with being a less profitable business, we're doing some work on improving the business. But, you know, I'm very, very bullish with the business. I mean, there's a great coverage throughout the world. We didn't have overlap and capability. You're really complimentary, and the team is extremely motivated. So the Amitec leadership style is having a positive effect on Faro. So we're very pleased with it.

And then last, you know, 25 was a year where I think we're all waiting for a short cycle recovery that never happened. And, you know, you've clearly stressed that your orders improved into the year and then continued to be strong in January. What kind of conversations are you having with your customers? Do you feel better that what's happening right now is not maybe a flash in the pan, but maybe more of a substantive recovery? Would appreciate any color.

If you go back and listen to our last couple of conference calls, we were feeling better through the quarters, too. We could see momentum building, and it seems to continue to build. So, you know, we've had a fantastic pipeline of opportunities, and more of those are starting to happen. And I just, you know, you had three years of negative PMI prints, and I think it's changing. It feels good for us. And, you know, you have a lot of – we got the positive segments that we talked about, And we got the power business now is well positioned and it's going to benefit from the build out of power capacity. The process business is seeing steady improvements and we're managing a strong pipeline. Future project activity remains extremely healthy. You look at a little bit of macro uncertainty around the broader decolonization, but at the same time, conditions remain constructive. of interest rate policies are positive m&a environment looks favorable um you know the industrial renaissance across the west should offset help us offset any kind of drag from the tariffs so you know we're going our business and we're feeling pretty good right now so you never know if it's long lasting but right now it's it's uh it feels feel solid and we're certainly being prudent with our guide because uh you know something like you mentioned happens and it weekends later in the year, but we don't see it.

Thanks so much.

Thank you, Andrew.

Thank you. Our next question comes from Jamie Cook from Truist Securities. Your line is open.

Hi, good morning. I guess my first question, Dave, can you just obviously, you did Faro, you did Kern, just sort of an update on how you're thinking about, you know, the M&A pipeline in 2026 and are there any sort of sizable deals that are out there? And then my second question, just on the, you know, implied margins for 2026 relative to the top line guide. You know, we talked about priced costs being positive. Obviously, I think FARA is still going to weigh on margins a bit. Is there any other factors that we should consider as we're thinking about margins across your segments that are unusual?

No, I think, Jane, I'll take the margin question first. I mean, we're firing on all cylinders in terms of margins. You know, if you look at our core operating margins, we're up 100 basis points in the quarter. So if you back out all the things you mentioned, they're very strong. Both groups, EIG was up 50 basis points. EMG on a core margin was up 310. And if you look at incrementals, our core incrementals were 45% in Q4. So, you know, that's very strong. And for 26, we've been a little more conservative. We're saying, you know, 35% reported incremental margins and 30 basis points of margin expansion. So 30 basis points of margin expansion, which is pretty typical for us going into each year, and we're thinking we can get 35% incrementals. And that'll be a little bit less than we got in 25, but it's more prudent. We're feeling good about it. There shouldn't be any surprises. Because with a business like ours, I think 31% EBITDA, every time we acquire businesses, they're coming in at a lower profit margin. So, yeah, that's why we try to give the core margins, and we communicate them, and we go through it all, and you have to think about it a little. But if we had a business that has a lot lower margins, like Zygo had essentially 15% EBITDA margin, so there's going to be initial dilution. And we have a tremendous capability of bringing those margins up. And the best way to look at that long term is our return on capital. If you look at our balance sheet, it doesn't lie. We have between a 12% and 13% return on capital. And that's how we know we're creating value for our shareholders.

Okay, so that was the genesis of my question. So it's just you being prudent versus anything else.

I think so. It really is. And then you talked about M&A. And, you know, we're excited about the businesses we've got done because we really can add a lot of value to Farrow and Kern. But we really have the opportunity to differentiate our performance with M&A in the next year or two because with our ability to operate businesses, our discipline, and really a key change in the pipeline, we really have a strong pipeline of deals right now. And as Dallas said, we have a balance sheet ready to act, ready to put to work. And the pipeline remains strong. We're actively looking at a number of high-quality deals. We could spend $5 billion to maintain our investment-grade credit rating. So the team is active, and we're excited. And there's really going to be a way for us to differentiate our performance over the next couple of years.

Thank you. Thank you. Our next question will come from Nicole DeBlaze from Deutsche Bank. Your line is open.

Yeah, thanks for the question. Good morning, guys.

Hi, Nicole.

Maybe just circling back on China, really encouraging to see it turn positive and nicely positive in the quarter. Dave, do you think we're seeing a turn in that market? If we could maybe double-click on what you're seeing in the individual businesses there and what your expectation is for 2026 as well.

Right. Right. China's a little different for us. I mean, we have, first of all, we have a fantastic team over there. We have just great, great long-term Amethek employees over there and do a great job of managing it. And we have products that are used by our customers in China to improve their manufacturing processes, you know, high-value manufacturing processes. We have products that they use to automate their process and build out their nuclear power infrastructure, electric vehicle industry. So a lot of our products are really suited to our customer base over there. So it's, you know, the overall, you know, the overall market, the overall country, I think you're seeing some deflation. I think you're seeing, you still have a real estate hangover, but in the places that we're playing, we still have strong positions. And, you know, And we're being conservative on how we're looking at that business, but it was good to see the change and get a low double-digit growth and driven by our process businesses, our power businesses, and our automation businesses all firing on all cylinders in China.

That's great. Thanks, Dave. And then just maybe following up on Jamie's question on M&A, it sounds like you're pretty fired up about the pipeline. Would you say, like, if you kind of think about your time running Amitech Amatek and compare today's pipeline versus what you've seen over the years. Is this like a stronger pipeline than normal or is it just, okay, our pipeline is always strong and this has been a focus of Amatek for some time? Thank you.

Yeah, the pipeline has always been strong, but I think right now the pipeline is filled with a good mix of normal quality deals and larger deals. So I think there's probably more larger deals than have been in our pipeline in a while. And larger deals, you know, we're not looking to buy a business that's even a quarter of us. We don't think you add value that way. A good bunch of businesses there that are of good chunky sizes for us. So as we get bigger, we've expanded the types of businesses we're looking at. And, you know, we're very pleased with, I mean, we're very disciplined. So, but at the same time, if we buy a business, you know, we're going to get the returns on capital. And we're optimistic. We're working very hard. We have a great team in M&A. We have about 11 people dedicated to M&A. There are very few companies in the industrial world that have the dedicated people to it, and all of our operators are also involved. So we have a good process. It's well-defined processes, the processes that work on deal sourcing, deal modeling, diligence, integration, and I think the secret sauce of Ametek is we have very strong business operators well ingrained in the emmetech culture well ingrained in the emmetech business system providing ownership for the delivery of financial metrics for each individual deal so and we learn something new from every deal it's uh we're experienced at it but but we're humble and we learn something new from every every deal and we share the knowledge and it just makes us

better thank you dave i'll pass it on thank you nicole thank you our next question comes from Chris Snyder from Morgan Stanley. Your line is open. Thank you. I wanted to follow up about the

2026 margin guide. It seems like on the math that Q1 margins would be down year on year again. I'm just looking at the 10% top line growth versus EPS up mid to high singles. So I guess, does that reflect some of the M&A headwinds still coming through in that year on year compare? And, you know, obviously you guys are guiding margins up for the year, so do you think they will, you know, turn back to expansion in Q2, or is that more of a back half event? Any just color on the trajectory there would be helpful. Thank you.

Yeah, Chris, I think in Q1 specifically, we got overall sales of 10%, and you got Farrow in there that's running at a lower margin, pretty sizable deal running at a lower margin. So if you just look at Q1 and you look at the year-on-year increase in sales and you apply a mid-20s contribution margin to it, it'll work out to our guide. I mean, I think below-the-line items essentially offset, and we're getting mid-20s on the contribution margin on the incremental business, and that'll be right in line with what we did.

Yeah, Chris, if you adjust.

Thank you. I appreciate that color. And then just to follow up, I'm staying on margins, and I guess maybe, you know, the inorganic margin opportunity or maybe the synergy opportunity on FARO and Paragon is the better way to phrase it. Can you talk about where we are on that? You know, Faro, I think you guys said, comes on mid-teens EBITDA. You guys see a pathway to, I think, double that to about 30, you know, any color on the path. And then Paragon is obviously closer to final state margins, but I think you guys have talked about maybe another 500 BIPs or so there. Can you just maybe kind of provide any sort of timeline on, you know, how those businesses are progressing against those targets? Thank you.

Yeah, I'll start with Paragon. Paragon is already at EBITDA margins that are now in line with Amitabh. By the people that are doing the work in that business, there's more room to go. So I think there's a whole next leg of, you know, margin improvement in Paragon that is going to occur over the next 12, 18 months, and it's going to occur incrementally. We do things incrementally at low risk, and that's going to happen. And then with Faro, you know, we're kind of in the beginning stages of it. And, you know, you saw some pretty heavy restructuring done early in the year. We're still doing some organizational work. There's an international infrastructure that we haven't dealt with yet in terms of duplication. So I think you'll see some benefits from Paragon this year. And, you know, Farrell is going to approve, but it's going to take us a couple of years to get it to 30. And it's going to be in some chunky improvements, but it's going to take us a couple of years to get it there.

Thank you, Dave. I appreciate that.

Thank you. Our next question comes from Julian Mitchell from Barclays. Your line is open.

Hi. Good morning. Good morning. Just maybe wanted to start with the orders, sort of trends in recent months. you know, as you said, things felt better into year end. December was good, but I suppose the absolute organic orders growth rate was, I think, steady year on year in the third and the fourth quarters at about 7%. So were there things sort of maybe help us understand, were there things moving around on specific markets within the orders or something geographically, any color as to how maybe orders look different in the fourth versus the third quarter?

I think it was pretty broad-based. I mean, we had, when I look at the fourth quarter, we had organic orders of 7%, as you said, so EIG and EMG. So it was broad-based, and it was a similar pattern from, in the book to bill of Amitech was 1.02.

Thanks very much. And when we're looking at the organic sales,

I think what you see is the EMG businesses picked up first and the EIG businesses, the process part of the EIG businesses are following later. And that's a typical pattern that we've had throughout history. So there's some time during the 2026 when we think the EIG, the process part of EIG is really going to inflect positive. And historically, we've had great contribution margins when that happens. But that's how it's happening. EMG happens first. EIG happens later. When you look at aerospace, it's been strong all along, and you look at that separately.

That's helpful. And Dave, just wanted to follow up on your points just now on thinking about the phasing of the segment. So when we look at organic sales growth for Amatek in 2026, maybe clarify, you know, what degree of sort of deceleration just from tougher comps you're dialing in inorganic growth through the year with that prudent framework in mind? And are we assuming then that the EIG business kind of exits the year, maybe organically growing a little bit faster because of that later pickup?

I don't know what's going to happen exactly because we're looking a long way out. But I think if you get into the second half of the year, EIG organics could be stronger and EMG organics could have a tougher comp.

Thank you. Thank you. Our next question will come from Joe Giordano from TD Cowan. Your line is open.

Hey, good morning, guys. Good morning, Joe. Apologies if someone asked this from kind of multitasking here a bit, but, Dave, can you, on the guide for process, I know you like to be cautious in the beginning of the year and markets far from certain here, but it feels a little conservative, low single digits coming off like an acceleration throughout the year and now going positive. Can you kind of frame maybe the puts and takes that's driving that view on initial view on process I can see that I mean it was

a we grew low single digits in Q4 and we guided low single digits for the year so Q4 was the first quarter process add positive low single digits so we're being a bit prudent but you know one quarter does not make make a year is

there a big spread in that segment between like what's getting better and what's kind of stable but not accelerating, maybe if there's a little bit more granularity we can get there?

Yeah, I think in that segment what you see is the semiconductor business is positive and the instrumentation sold, the metals businesses are positive and the Rollin business that we talked about earlier is positive. So a lot of things are positive and the places that are the oil and gas and the research are a little bit less than those those positive segments yep that makes that

makes sense um could you maybe give us a little color on the new deal like in terms of the size of the business and the the maybe the margin opportunity

there yeah yes it's really a technology deal and we're not disclosing terms we have an agreement that we're not disclosing terms it's a smaller deal It's a technology deal, and it's a really, really interesting business. They're a leading provider of advanced eye care testing instruments, and optometrists are trying to find the initial signs of diabetic retinopathy, and they're doing that with structural testing, and they're testing your eye. They're looking at your eye. You're trying to see things. but this is a an actual electrical response and it's not a portable device there was a technique that you use to do the test the test was a expensive it was very large piece of equipment but they innovation was to make it a really portable instrument and it's really going to help a lot of people and it's kind of a technique that's very very growing rapidly small but growing rapidly, and most of the sales are in the U.S., and there's about 60 employees near D.C., in Germantown, Maryland, and it fits right into our record business. Our Alta Precision Technology business has a business that sells this type of equipment. It's just an additional product line, so we're really happy about it. We got its adjacent technology. It broadens our portfolio. It lets us leverage our channels and leverage their channels. And this business has a recurring revenue of nearly 40% from these tests, from these sensor strips that are placed on the I. So it's really good technology. We're pleased with it, and we're not going to disclose the terms, though. It's a smaller deal, technology deal. Thank you.

Thank you. Our next question comes from Steve Barger from KeyBank Capital Markets. Your line is open.

Hey, everyone. This is Christian's dialogue for Steve Barger. I just have one question. A few years ago, EMG operated in a mid to high 20% operating margin. With the recent acquisitions and current mix, is it possible for you guys to get back there organically, or does that likely come from acquisitions? Just really trying to get any thoughts of how you're thinking about EMG broadly and what you're targeting over the next few years.

Yeah, I think seasonally, EMG is usually a little bit lower in Q4 than the other quarters because of some dynamics in the business. But I don't think there's any reason that we won't be operating at that. I think we did operate.

Yeah, I think if you go back a couple of years, like you stated, we track back maybe 60%, and I think we're on track to hit those.

Great. Thank you.

Thank you. Our next question comes from Scott Graham from Seaport Research Partners. Your line is open. Hey, good morning.

Thanks for taking the question. There's actually two of them. I don't remember, Dave, the last time we saw a vitality of 30%. I was hoping you would unbundle that maybe a little bit to or maybe is there some defense in there? Is there this maybe chasing some data center sales in there? Kind of tell us maybe where some of those are going specifically, if you could, and their impact on the organic.

Yeah, 30% is a good number, Scott. We're very pleased with that. There are some data center sales on that. We talked about in the last call that we've reconfigured some of our products for that market that were sold to the defense market. Those are certainly contributing to that. But there's just the engineering capability that the company is unquestioned, and they're really developing some good things. Our customers are very pleased with them with the uptick, and it makes us feel confident going into a strengthening market that we get the right products that you need. But it's really bottom-up, as you know. So it's all our businesses, and we're not telling a business to develop this or develop that. It's organic, and there's just very, very viable product development plans, technology roadmaps, and we're optimistic about what we've done with our products and our technology.

Okay. Thank you. The follow-up is simple. Is the defense budget potentially reaching $1.5 trillion at some point next couple of years? Do you need acquisitions maybe to get you a little bit more broadly exposed to sort of have dibs on some of that? Or how do you feel about your defense business? I know that there's nothing specific in the budget on it. It's just a number. But how do you feel about maybe getting after some of that business? Do you need a couple of deals to help you?

Yeah, we'd love to do a deal in the defense industry, but we have fully developed product lines in the business cases. For the computing area, I mentioned the air technology. I mentioned our road front business and the advanced cooling. I mentioned our power business, selling power systems to UAVs. So we're really competitive, and that business is doing very well. So we don't need an acquisition to continue growing. And we actually have a little – our aerospace and defense business is about 18% of sales. We have a little more defense sales than commercial sales. So we're in a pretty good position there. legacy centers on aircraft selling to both commercial and defense aircraft to some of the more lately some of the modern more things we've done in the recent years so it's pretty wide range it's same strategy we're focused on niche technology things we're really good at and we have plenty of people knocking on our door and as i mentioned the european you know the european starting to focus on their own defense and their own protection, definitely creating opportunities for us.

Thank you. Thank you. Our next question comes from Rob Wertheimer from Milius Research. Your line is open.

Hi, and thanks. I know we're getting towards the end of the call. I had sort of a general question that you touched on with Andrew, I guess. But on Paragon, it seems like a lot of things have gone well. And this may be a question as much about Amitech as about Paragon. But I wonder if you could just, you know, just give us insight into what you've done and what has made the most positive improvements there as sort of a way of learning about the company again.

Yeah, well, I think the most important thing is we bought a very good business. And if you remember when we bought it, you know, people were worried about it. We weren't worried because we knew we had a good business. We knew we had a good team. and, you know, the consumable surgical instruments that they manufacture are good recurring revenue. They're a leader in implantable components, so we bought a good business. And we bought a business that, quite honestly, was under-managed on the operations side, so we've done a lot of good work to improve that operations, combined it with one of our businesses who has great capability in another part of it. Similar to the FARO model, we have bought a business in a market we knew. We have some capability. We've restructured the business to be more focused on customers, more focused on understanding the P&L, and we're bringing Amitex global capabilities to it. So it's kind of a playbook that we apply quite often, and Paragon is going to lead the way, but FARO is right behind them.

Perfect. Thank you.

Thank you. And our next question will come from Robert Mason from Baird. Your line is open.

Yes, good morning. Thanks for squeezing me in. Just one question. Dave, to go back to the process business, it does sound like your industrial business is there more likely to lead on growth. And you made a comment just around some of the research areas. How are you expecting those research areas, R&D exposed areas, to play out through the year? Do you think they have a chance to be flat or even up a little this year, start to see some turn?

I do, and there's always time for you, Rob. So I think in the research area, what you really saw in the U.S. was there was a little bit of a, during the dog's time, and that's right in itself. So in a lot of areas of research that we happen to be particularly biased to, there's a lot of nuclear research going on. In the materials area, there's a lot of research going on to find new materials, to replace other materials with rare earth metals. There's a lot of research going on there. So in our Kimika business, there's high-end research. There's high-end research going into nuclear. And the other thing that caused us some problems in 2025, which has gone away, was that when the tariffs originally were put in place, they caused substantial pricing disconnects for us and our customers, and now we've worked through that. So as long as tariffs stay in about the same range, that won't be an issue. So I do think that we have the potential to grow our research business in 26.

Very good. Thanks, Doug.

Thank you. And I am showing no further questions from our phone lines. I'd now like to turn the conference back over to Kevin Coleman for any closing remarks.

Thank you again, Crystal. And thanks, everyone, for joining our call today. And as a reminder, replay of the webcast may be accessed in the Investor section of Amatech.com. Thanks, all.

Thank you. This concludes today's program. Thank you for your participation. You may now disconnect.